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Abstract
Background: Science, technology and innovation have long played a role in Ghana’s vision for development,
including in improving its health outcomes. However, so far little research has been conducted on Ghana’s
capacity for health innovation to address local diseases. This research aims to fill that gap, mapping out the key
actors involved, highlighting examples of indigenous innovation, setting out the challenges ahead and outlining
recommendations for strengthening Ghana’s health innovation system.
Methods: Case study research methodology was used. Data were collected through reviews of academic literature
and policy documents and through open-ended, face-to-face interviews with 48 people from across the science-
based health innovation system. Data was collected over three visits to Ghana from February 2007 to August 2008,
and stakeholders engaged subsequently.
Results: Ghana has strengths which could underpin science-based health innovation in the future, including health
and biosciences research institutions with strong foreign linkages and donor support; a relatively strong regulatory
system which is building capacity in other West African countries; the beginnings of new funding forms such as
venture capital; and the return of professionals from the diaspora, bringing expertise and contacts. Some health
products and services are already being developed in Ghana by individual entrepreneurs, which are innovative in
the sense of being new to the country and, in some cases, the continent. They include essential medicines, raw
pharmaceutical materials, new formulations for pediatric use and plant medicines at various stages of
development.
Conclusions: While Ghana has many institutions concerned with health research and its commercialization, their
ability to work together to address clear health goals is low. If Ghana is to capitalize on its assets, including political
and macroeconomic stability which underpin investment in health enterprises, it needs to improve the health
innovation environment through increasing support for its small firms; coordinating policies; and beginning a
dialogue with donors on how health research can create locally-owned knowledge and be more demand-driven.
Mobilizing stakeholders around health product development areas, such as traditional medicines and diagnostics,
would help to create trust between groups and build a stronger health innovation system.
Background
The first African country to gain independence (from
the British in 1957), Ghana has long been seen as a lea-
der in Africa. With its plentiful natural resources
(cocoa, gold, and recently-discovered oil), stable
governance situation, long-standing universities and
research institutions and improving communications
infrastructure, many factors are in Ghana’s favour when
it comes to economic development. Recent years have
indeed seen improvements in Ghana’s macroeconomic
environment - growth was roughly 6% in 2008 and 2009
[1]. In 2009 the World Bank rated Ghana as the best
place to do business in West Africa [2], in part due to
the stable political system which has increased the confi-
dence of investors.
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Science and technology (S&T) have formed part of
Ghana’s development vision for decades, dating back to
1964 when the government under president Kwame
Nkrumah published its ‘Seven year plan for national
reconstruction and development’ which saw S&T as
central to industrialization [3]. Much more recently,
Ghana’s guiding policy documents cite the importance
of S&T for improving productivity and socioeconomic
outcomes [4-6]. Nevertheless, the concerted application
of S&T to improve development has generally been elu-
sive. Investment in universities and research institutions
is low, and several studies still show Ghana to be a poor
adopter, user and generator of technology [7,8]. Foreign
firms cite Ghana’s lack of human resources, poor infra-
structure, and low levels of technology as their main
barriers to increased foreign investment [7].
One area where S&T has great potential to improve
outcomes is health. Disease burden remains high in
Ghana, with malaria the main cause of mortality and
morbidity, accounting for about 21% of under-five
deaths and 37% of all hospital admissions [9,10]. Other
common diseases include cholera, tuberculosis and
respiratory tract infections and there are currently
around 260,000 people living with HIV/AIDS in Ghana
[11]. Endemic neglected diseases include schistosomiasis,
onchocerciasis (river blindness) and lymphatic filariasis
(elephantiasis). Maternal mortality remains one of Gha-
na’s most pressing health problems and has recently
been declared a ‘national emergency’ after indicators
worsened [12].
Harnessing S&T to develop appropriate and affordable
health solutions for Ghana, and indeed the wider West
African region, has the potential to contribute to
improved health outcomes as well as to offer opportu-
nities for entrepreneurial activity that could add dyna-
mism to the economy. Currently, Ghana’s health sector
has a mix of both pharmaceutical and traditional herbal
or plant medicines (traditional medicine encompasses a
range of knowledge, beliefs and practices [13,14] but
here we use it to refer to herbal or plant remedies for
specific diseases). Drugs are predominantly imported
and are estimated to constitute 60 - 80 % of the cost of
health care in Ghana [15]. Plant medicines, which are
typically cheaper than pharmaceuticals, are also easier to
access in rural areas of the country [16].
In this paper, we present research on science-based
health innovation in Ghana, including biotechnology. By
science-based health innovation, we mean technological
innovation across a spectrum of sophistication, from
vaccines, pharmaceuticals, and medical devices to some
plant medicines where attempts to scientifically standar-
dize or characterize medicines have been made. We take
a broad definition of innovation as not only new-to-the-
world innovation, but also the diffusion, adaptation and
use of technologies. We use the OECD definition of bio-
technology: ‘the application of science and technology to
living organisms, as well as the parts, products and
models thereof, to alter living or non-living materials for
the production of knowledge, goods and services’ [17].
The purpose of this paper is to describe and analyze
science-based health innovation using an innovation
system framework, which takes into account the wide
variety of stakeholders who contribute to the innova-
tion process and emphasizes the dynamic interaction
and knowledge flow between them [18]. To date there
has been little research on science-based health pro-
duct innovation in Ghana, the exception being Esseg-
bey ’s 2003 innovation systems study on Ghana’s
biopharmaceutical capacity [16]. This work builds on
that study and was undertaken at the invitation of the
late Major Courage Quashigah, former Minister of
Health, Ghana.
Methods
A case study research methodology was used in this
study [19] . Data were collected through reviews of aca-
demic literature and policy documents and through
open-ended, face-to-face interviews in Ghana. Intervie-
wees were identified through purposive and snowball
sampling; we interviewed 48 individuals from across the
science-based health innovation system, including
government officials (n=7), researchers (n=18), entrepre-
neurs (n=10), international donors (n=9) and non-
governmental organization representatives (n=4) over
three visits to Ghana from February 2007 to August
2008. We held a workshop in Ghana to discuss our
initial findings in August 2007 and continued to engage
stakeholders to address some of the challenges identified
by this study throughout 2008 and into 2009.
When data for this study was collected, the govern-
ment was that of the New Patriotic Party (NPP) under
President Kufour. On 7 January 2009 President Atta-
Mills and his New Democratic Congress (NDC) party
assumed power. The results presented here are from the
NPP period but, where significant developments have
since occurred under the NDC, these are indicated.
All quotes are from the interviews unless noted, and
with permission. This study was approved by the Office
of Research Ethics of the University of Toronto.
Results and discussion
In this section we discuss the roles of some of the prin-
cipal actors in Ghana’s science-based health innovation
system as identified by preliminary research and by the
general innovation systems literature - government,
research institutes and universities, the private sector,
and non-governmental organizations (NGOs) and
donors.
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Government
Government policies have been shown to play a large
role in establishing an environment conducive to inno-
vation in other developing countries, helping to set S&T
priorities and funding levels, regulate technologies and
support private sector growth [20,21].
Ghana has a variety of policies that link science to
development and growth objectives, and that could
therefore have implications for the application of health
research to solve local problems. For example, Ghana’s
first National S&T policy was developed in 2000 and
outlined measures to address development challenges in
areas such as health, agriculture and ICT using ‘innova-
tive and modern technologies’, including biotechnology.
It also aimed to improve the S&T environment through,
for example, better technology education and increasing
awareness of intellectual property rights [22]. Ghana’s
Poverty Reduction Strategy II (GPRS II), which sets the
target for Ghana to achieve a per capita income of at
least US$1000 by the year 2015, sees S&T as underpin-
ning industrial growth, encouraging the ‘adoption of
appropriate technologies, both local and foreign, with
the capacity to improve productivity and efficiency in
the agricultural, industrial and services sectors’. How-
ever, our research showed little recognition of these
aims in the health sector and weak implementation of
S&T-driven goals. A number of interviewees in this
study, including researchers at universities, were una-
ware that the 2000 S&T policy even existed and used its
absence to explain poor levels of innovation in the
health sector.
Government spending on research and development
(R&D), including health research, has generally been
fluctuating and low. Though statistics are difficult to
obtain, it appears that funding levels were higher in the
1970s and 1980s than the next two decades [23].
Adarkwa cites spending between 0.3% and 0.35% of
GDP for 2002-03 [24], and UNCTAD in 2003 noted
that “[a]llocations to the Ministry of Environment,
Science and Technology constitute only about 0.25 per-
cent of the GDP, a reflection of the importance
accorded to science and technology and the environ-
ment. Moreover, only about two-fifths of the Ministry’s
budget is used for research” [25]. This is far short of the
African Union commitment of 1.0% minimum allocation
of national budgets, and instead most funding for health
R&D is from foreign sources.
Our research suggests a lack of strong leadership
around S&T and poor co-ordination between the var-
ious Ministries as explanations for these funding and
policy implementation challenges. This is borne out by
the changing status of science at the ministerial level. In
2000, the relevant Ministry was that of Environment,
Science and Technology (MEST); during our study, S&T
formed part of the Ministry of Science, Education and
Sport; since the NDC government took power, MEST
has been reinstated.
In the health sector, priorities and programmes are set
by the Ministry of Health (MOH), which had a budget
of~$500m USD in 2007 [26] (approximately 14% of the
Government budget that year), most of which was on
health workers salaries. Ghana’s current 5-year program
of work (2007-2011) highlights a range of goals includ-
ing addressing communicable diseases such as HIV and
malaria, reducing risk factors associated with non-com-
municable diseases, scaling up high-impact health inter-
ventions in areas such as nutrition and maternal health.
A major focus has been on improving access of health
services to the poor. Up until recently, patients paid out
of pocket according to a ‘cash-and-carry’ system for
access to health services. However, a National Health
Insurance Scheme was put in place in 2004 with the
aim of improving financial access to quality health ser-
vices [27].
The MOH funds health research, largely through the
Health Research Unit of the Ghana Health Service, the
executive arm of the MOH, which has three field sta-
tions across the country (Navrongo, Kintampo and
Dodowa). These sites have been involved in some excep-
tional examples of public health research — for exam-
ple, the Vitamin A supplementation trials carried out at
Navrongo until 1992 were some of the largest field trials
ever carried out in Africa, and showed a 23% reduction
in child deaths. The findings led to changes in national
policy as well as policies of international agencies such
as the WHO, UNICEF, and World Bank [28], which
demonstrates that links between government and
research exist, as well as links into the global donor
community. Our research suggests the MOH is less
strongly connected to other sources of health knowl-
edge, such as the universities, though links do exist. The
main challenge for innovation is the weak relationship
between MOH priorities and the local productive sector.
In an attempt to address this problem, the MOH’s
Health Research Agenda put forward the idea of sup-
porting a ‘health industry’ – microbusinesses that
improve public health through the provision of a pro-
duct, service or intervention [29]. This approach is
viewed partially as a mechanism to supplement an over-
stretched health budget, but also reflects dissatisfaction
that almost all health products used in Ghana are
imported— most allopathic drugs, all ITNs (insecticide-
treated nets) and even hospital beds. Eddie Addai, a for-
mer Director at the MOH, acknowledged that, in terms
of public health interventions, ‘what we haven’t done as
a country is approach [interventions] from a business
perspective. We’ve approached them from a science per-
spective. And we’ve left the business to grow, as it were’.
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A fund of ~US$300,000-400,000 was set aside for
these activities in the year 2006-2007, aiming to support
novel ideas for translation of health research. However,
limitations to this initiative proved considerable - per-
sonnel and time constraints within government, a lack
of business knowledge within the Ministry, and an
absence of links to other Ministries with an industry
focus, and of links to industry itself. The fact that this
‘out-of-the-box’ policy was developed and integrated
into the Ministry’s plans for research is encouraging;
however in practice resource constraints and the prece-
dence of other health policies means than there is little
room for policy experimentation and novel ideas remain
isolated ones.
Again, lack of alignment between government Minis-
tries, aims and policies can be seen though the example
of the local production of health products. In terms of
procurement, the government gives a 15% price prefer-
ence to local producers and Ghana’s National Drug Pol-
icy acknowledges that local manufacture has been
weighed down by free market policies and seeks to sup-
port the private sector through funds to develop the raw
material base for the pharmaceutical and herbal indus-
tries; technical support; and the encouragement of
exportation. On the other hand, GPRS II does not high-
light pharmaceuticals as a key sector for support, though
it does aim to improve availability and access on a sus-
tainable basis.
Alongside the allopathic or biomedical system, tradi-
tional medicine remains highly popular in Ghana. At
least 60% of Ghanaians use traditional medicine as the
first port-of-call in primary care, particularly in rural
areas: ‘every village or hamlet has a traditional resource
for health care within easy access’ [16]. The MOH
therefore considers improving traditional medicine qual-
ity and standardizing practice as a potential route to
considerable health returns, and has put in place a num-
ber of policies to encourage this over the years. This has
been consolidated in a comprehensive National Strategic
Plan for Traditional and Alternative Medicine Develop-
ment 2005-2009, based on WHO resolutions and con-
ventions. In practice this Plan sets an ambitious agenda,
encompassing a range of stakeholders from traditional
healers to policy-makers, and setting a large number of
diffuse targets – all of which makes the Plan challenging
to implement. Again, there are examples of disjointed
policies: there are no TMs on the Essential Drugs List,
for example, despite the fact that the Government seeks
to promote their use.
As in all countries, regulation in Ghana is an impor-
tant aspect of health innovation, setting standards for
product quality and safety, and influencing access to
markets. Health products in Ghana – including biome-
dical drugs, traditional medicines, and medical devices
(e.g. bednets, diagnostics, condoms) whether locally
manufactured or imported – are regulated by the Food
and Drugs Board (FDB). The FDB also regulates the
conduct of clinical trials. For traditional medicines, the
FDB seeks evidence of safety over a two-year period but
efficacy testing is not required, making regulation of
plant medicine fundamentally different from pharma-
ceutical development. Though counterfeit drugs are a
problem in Ghana, they are considered to be less so
than in other countries in the region [30].
Our research suggests that the Ghanaian FDB is
amongst the strongest in West Africa, with well-trained
and active staff. A number of firms in our sample
singled out the FDB as a helpful government unit. Drug
testing is carried out at the National Quality Control
Laboratory (NQCL) under the FDB. The FDB has a 5-
year plan to upgrade infrastructure, including a new
National Quality Control Lab which they will seek to
accredit with the World Health Organization (WHO)
and International Organization for Standardization
(ISO). The FDB also offers Good Manufacturing Prac-
tice (GMP) training for firms, a process they are trying
to encourage so that firms can better meet international
standards. There is also a collaboration with USAID
(with technical assistance provided by Unites States
Pharmacopeia), aiming at building capacity to monitor
the market for illicit and sub-standard drug. However,
funds are restricted, and progress in these areas sporadic
[31]. Regulators also face a challenge in balancing a
push towards international GMP standards with sup-
porting local firms that will need time and assistance to
meet such standards.
The FDB is strongly involved with other countries in
the region: it has helped to train regulators in Sierra
Leone, for example, and works with the Economic Com-
munity of West African States (ECOWAS) through
which a regional regulatory body for West Africa has
been discussed. Our study showed strong support for
regulatory harmonization; among other benefits, access
to a market of 270 million people would be a major
incentive for local health innovation. Ghana and Nigeria
have similar drug regulatory structures based on the US
FDA system, and we observed that personal linkages
between executives of the FDBs in both countries meant
that discussions on regulatory harmonization have taken
place.
Another important policy area for health innovation is
intellectual property regulation. Ghana has been a Mem-
ber and Signatory to the TRIPS (Trade Related Aspects
of Intellectual Property) Agreement since January 1995.
Ghana is not considered a Least Developed Country by
the World Trade Organization, and as such cannot take
advantage of time extensions for TRIPS compliance.
The 2003 Patent Act therefore amended Ghana’s
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previous Patent Law of 1992 in order to ensure all
TRIPS obligations were met. An IP office exists in the
Registrar-General’s office; however, our evidence showed
very low levels of patenting of indigenous research,
including in health. The knowledge, systems and costs
needed for patenting mean it is simply not a realistic or
relevant proposal for researchers. One interviewee said
‘the process is too cumbersome. For developing coun-
tries, I think it will take some time to get people patent-
ing; it’s going to take a lot of time and energy’. This
applies also to the field of traditional medicine where
the question of how to protect indigenous or commu-
nity knowledge is very complex. As yet there is no spe-
cific protection for indigenous knowledge in Ghana,
though draft regulations were prepared in 2007.
Instead, interviewees associated IP in Ghana with glo-
bal regulation which can restrict access to medicines.
Ghana’s 2003 Patent Act includes some provisions
which may improve access to medicines (such as parallel
importation of lower-cost pharmaceuticals) and some
which may not (doubling the time for patent protection
to 20 years) [32]. However, sufficient legal grounds exist
to use compulsory licensing to address its public health
concerns, a situation that has been demonstrated by one
Ghanaian firm which is making 7 Anti-retrovirals
(ARVs) under compulsory licenses.
Research institutes and universities
Our research showed that there are several Ghanaian
institutions involved in international health research, lar-
gely in partnership with overseas universities and donor
organizations. However, there is evidence that the capa-
city to train students to a high level, important for tech-
nologically-intensive areas, remains small. In 2002
Ghana’s higher education system contained just 127
PhD students [33] and S&T numbers in the system have
decreased [34]. A lack of qualified applicants, limited
laboratory infrastructure and poor job prospects are
contributing factors in this decline [35].
University of Ghana
The University of Ghana gained full university status in
1961, and now has nearly 30,000 students (including
roughly 1,800 graduate students) [36]. It has a number
of departments and institutes relevant to biotechnology
and to health, foremost among them the Noguchi Mem-
orial Institute for Medical Research, which has roughly
260 staff working on communicable disease, nutrition,
and non-communicable diseases (e.g. cancer, sickle cell,
diabetes). Noguchi hosts a variety of laboratories for
neglected diseases including a WHO-accredited polio
laboratory, the lymphatic filariasis support centre for
Africa, a clinical trial facility and rotavirus reference
laboratory. Researchers are involved in a range of local
and international collaborations exist – with the
Ministry of Health, Ghana AIDS Commission, Yale
University Medical School, Duke University, and Tokyo
Medical and Dental University, to name a few.
According to the University’s annual report for the aca-
demic year 2007/2008, researchers across the University
published about 50 health research papers in interna-
tional journals and 7 in African ones; the highest number
of publications was on HIV/AIDS, Buruli Ulcer and
malaria [37]. Interestingly, almost without exception
health research projects at the University, including those
at Noguchi, were funded by external agencies including
World Health Organization, the Department for Interna-
tional Development (UK), USAID, UNICEF, and the Bill
& Melinda Gates Foundation.
Despite the volume of health research, its application
and commercialization is limited. Our research showed
an absence of patenting, industrial links and technology
transfer capacity. A pertinent example of this is the case
of a dipstick test for urinary schistosomiasis (the second
most prevalent parasitic disease after malaria), which
was developed by researchers at Noguchi. Based on
monoclonal antibody technology, the test was developed
to prototype stage but no further. One of the research-
ers involved cited lack of a reward system for innova-
tion, uncertainty about profitability, and the reliance on
imported solutions to local problems as specific barriers
to product development. It could be added that lack of
demand from the private sector – either locally or else-
where – is another reason for the stagnation of potential
health solutions within laboratories.
Kwame Nkrumah University of Science and Technology
(KNUST)
KNUST trains students and carries out research in a
range of biological and physical sciences. One of its
main centers for health research is the Kumasi Centre
for Collaborative Research, a joint venture between the
Ministry of Health, KNUST and the Bernhard-Nocht-
Institute for Tropical Medicine in Hamburg, Germany.
The Centre acts as an international platform for biome-
dical research into tropical diseases, and contains mod-
ern laboratory facilities for parasitology, molecular
biology and bacteriology.
As partners in the Malaria Vaccine Initiative, a global
program of the international nonprofit organization
PATH to accelerate the development of malaria vac-
cines, the Centre and the KNUST medical school are
testing the first promising malaria vaccine product from
GlaxoSmithKline, RTS,S (together with 8 other sites in
Africa). Phase II trials showed that RTS,S was efficacious
for at least 18 months in reducing clinical malaria by 35
percent, and severe malaria by 49 percent [38,39]. Phase
III began in May 2009 and is scheduled to take 2 years
and enrol up to 16,000 patients. The project is an exam-
ple of how involvement with practical global health
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initiatives can enable capacity building: the Centre has
built clinical trial capacity in the Kumasi region,
enabling it to retain locally-qualified technical staff and
offer them training opportunities in Good Clinical Prac-
tice and Good Laboratory Practice. These types of
opportunity are vitally important for helping to stem the
brain drain from health institutions. Professor Kruppa,
the Centre’s Director, highlighted that in the first year
of KNUST BSc course in lab technologies, ‘the first
batch after three years went completely abroad. Every
single person went abroad’. Other findings support this;
it is estimated that 47% of Ghana’s college-educated
graduates living abroad [40] and around 70% of
Ghanaian medical officers trained in the 1990s have left
the country [41].
In another example of locally-generated knowledge
translation making a major impact on public health, the
Centre, in conjunction with international partners, has
developed a new treatment regimen for the diseases onch-
ocerciasis (river blindness) and elephantiasis, which is
caused by worms spread by the black fly. After clinical
trials and publication [42,43] this approach has spread to
other developing countries in Africa and Asia and received
funding from the Bill & Melinda Gates Foundation, which
aims to make the treatment regimen compatible with
mass drug administration programs.
Technology transfer does occur at KNUST, largely at
a micro-scale and around ‘low-tech’ products, with the
help of its Technology Consultancy Centre, a long-
standing group which fulfills ‘the university’s third role:
that of service to the community‘[44]. Examples include
projects in engineering, nutrition and sanitation, work-
ing strongly with the local community and to some
extent with the Ministry of Health. Staff at the Centre
see numerous opportunities for further knowledge
translation and commercialization in health, though
they have historically been hindered by a severe lack of
resources and of links with the professional private sec-
tor. Our research found evidence of frustration that the
government is failing to challenge local scientists to
come up with solutions, and instead seeking technical
expertise from outside the country.
Centre for Scientific Reseach into Plant Medicine (CSRPM)
Research in traditional herbal medicine is well-estab-
lished in Ghana, with CSRPM, established in 1975, the
main public research body. The Centre conducts
research in phytochemistry and toxicity, both for regula-
tory and quality control purposes, and has facilities to
carry out animal studies. Focus is on the safety of pro-
ducts, relying on in-house safety studies as well as docu-
mented and community ethnobotanical knowledge.
Efficacy studies extend to in vivo animal testing but
there have been no full-scale human clinical trials,
which are hugely costly and not required by the FDB,
which approves herbal medicines by relying on safety,
not efficacy, data.
CSRPM has developed about 35 products, treating
indications such as asthma, sickle cell anemia, and
malaria, which it distributes through its clinic, which at
busy times sees up to 200 people per day. One product,
for the treatment of arthritis, is exported to Europe and
the US.
No intellectual property has yet been generated and
Dr Okine, CSRPM’s Director, recognizes that ‘there are
grey areas of IP rights, especially with natural products’.
At the point of interview, the Centre was attempting to
work out IP modalities for the knowledge it receives
from herbalists, acknowledging that traditional medicine
is for the most part community knowledge. There is no
national guidance on this issue yet.
Unlike research groups in the biomedical sphere, the
CSRPM has managed to spin out its health knowledge
to commercial ends. It also seems to be well-linked to a
number of other groups in an exchange of knowledge. It
has links to local traditional healers as well as to firms
in the beverage industry, for which it produces plant
extracts for flavoring, such as that from African maho-
gany (Khaya senegelensis). The on-site clinic also sug-
gests stronger links to end users than in the
pharmaceutical sphere. Finally, the Centre accepts
interns from KNUST’s herbal medicine course and links
them to local herbalists.
Council for Scientific and Industrial Research
The Council for Scientific and Industrial Research
(CSIR) was founded shortly after independence, and
later re-established by CSIR Act 1996 (Act 521) with a
mission ‘to generate and apply innovative technologies
which efficiently and effectively exploit Science and
Technology for socio-economic development in the cri-
tical areas of agriculture, industry, health and environ-
ment, and improve scientific culture of the civil society’.
CSIR comprises 14 research institutions, employs
~3,800 staff and is mandated to coordinate scientific
research across the country as a whole. Eight of CSIR’s
institutes cover agriculture; the others address animal,
water, industrial research, construction, S&T informa-
tion and science policy research. Although none of
CSIR’s Institutes focus specifically on health, the poten-
tial outputs of agricultural and water research, for exam-
ple, could have large indirect health impacts through
improved nutrition and sanitation.
An interesting aspect of CSIR’s work with lessons for
the role of innovation in Ghana is its efforts to align
with the needs of industry, and to generate 30% of fund-
ing from external sources such as commercial activity
and consultancy (a funding stream known as Internally-
Generated Funds or IGF). Currently a commercial direc-
tor exists to stimulate technology transfer and make
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CSIR’s research more appealing to the private sector.
However it was conceded by interviewees that this was
a very difficult goal to achieve – lack of strong links
with industry and understanding by researchers of the
mechanisms of product development have hindered the
process, and the policy effectively puts the burden for
‘commercialization’ onto individual researchers, without
structural support. Furthermore, services were the main
route to income generation, not necessarily adding to




Pharmaceutical production in Ghana is 50 years old, as
old as the country itself. There are approximately 40
pharmaceutical companies in Ghana as of 2009 and the
number is growing. These include both foreign firms
and locally-owned producers such as Starwin, Kina-
pharma, Ayrton Pharmaceuticals and Ernest Chemists.
Local firms are almost entirely focused on generic over
the counter medicines such as antibiotics, analgesics,
and anti-infectives. Branded products (i.e. generic pro-
ducts branded by a company) are also popular and pre-
sent a way for firms to distinguish their products from
many similar ones. It is believed that due to an oversup-
ply of production and fierce competition most firms are
producing under capacity [15]. The pharmaceutical mar-
ket is approximately 30% locally produced and 70%
imported products.
A few firms are producing essential medicines, though
these are largely provided by donors funds and sourced
internationally. For example, anti-retrovirals (ARVs) are
largely supplied by Indian companies such as Cipla and
Ranbaxy and anti-malarials supplied by firms in India
and China. It is difficult to obtain statistics for R&D in
the private sector, but our evidence suggests that little
formal R&D is taking place, mainly in the area of inter-
nal quality control.
DanAdams Pharmaceuticals, founded in 2004, is cur-
rently the only ARV manufacturer in Ghana – indeed,
in the Economic Community of West African States
(ECOWAS) region as a whole. Started as a joint Chi-
nese-Ghanaian venture, as of 2007 it became a wholly
Ghanaian enterprise focused on producing medicines
again HIV/AIDS, malaria and other infectious diseases.
Its founder, Yaw Gyamfi, a US-trained pharmacist,
returned to Ghana motivated to address drug shortages
in the country. Revenues generated from a community
pharmacy practice, still in operation, were used to build
a manufacturing facility, and the firm now manufactures
13 generic ARVs as well as antimalarials, anti-TB medi-
cations, analgesics and other drugs used for treatment
of opportunistic infections in HIV/AIDS patients, and
functions at GMP standards. Most of the initial ARVs
the firm began by manufacturing were off-patent, but
later ones, such as second-generation ARVs to be given
to patients who were building resistance, are manufac-
tured under compulsory licenses sought by the Gha-
naian government. More recently, DanAdams has
negotiated voluntary licenses – for example, it has an
immunity-from-suit agreement with Bristol Myers
Squibb for certain products.
The company has developed a number of innovative
drug formulations, such as Camosunate PED, a paedia-
tric antimalarial (containing amodiaquine, artesunate
and paracetamol) produced in sachet form for ease of
use. Camosunate PED is sold in Cote d’Ivoire, a rare
example of penetration of the Francophone market, and
is registered in a range of other West African countries.
DanAdams has authorisation to market its ARVs in Bur-
kino Faso, Sierra Leone, Liberia, Cote d’Ivoire and
Ghana. However, WHO pre-qualification has become
the main focus of efforts as it is a prerequisite of donors,
such as the Global Fund, seeking to procure essential
medicines.
LaGray Pharmaceuticals, founded by returnees from
the Ghanaian and Nigerian diasporas, is also pushing
boundaries. It has set up an international-standard man-
ufacturing facility for the production of active pharma-
ceutical ingredients (APIs) – the only such facility in
sub-Saharan Africa outside of South Africa – in order
to increase self-sufficiency of drug production for the
region, and to counter the fact that there are a large
number of poor-quality imports. Currently, all APIs
used in Ghana are imported, mainly from India.
LaGray’s current product portfolio includes azithromy-
cin, dermatologicals for opportunistic bacterial and fun-
gal infections, and anti-infectives, with anti-retrovirals,
anti-malarials and antihypertensives in the pipeline. In
time, the firm is interested in manufacturing drugs for
chronic disease indications such as diabetes. Prices are
marginally less than imports, and LaGray uses specially-
made hologram boxes to reduce possibility of counter-
feiting of their products. LaGray is seeking to access
regional markets, and have products filed with regula-
tory authorities in Nigeria, Togo, Benin, Senegal, and
Cote D’Ivoire.
Plant medicines
The majority of all interviewees across the whole inno-
vation system felt that the most promising area of health
innovation for Ghana was in herbal or plant medicine,
and that the current state of innovation in the field did
not do justice to Ghana’s knowledge and potential in
this area. Partly this is due to lack of linkages between
researchers and industry. Yaw Gyamfi, Dan Adams’
CEO, acknowledged that firms and researchers did not
interact. He pointed out that, for the future, ‘if there’s
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any collaboration at all, it has got to be in the area of
research and development, whereby we’ll be looking at
not only orthodox medication but herbal, because that
is the future of our country’.
There are other challenges too. Phyto-Riker, formerly
GIHOC Pharmaceuticals (a government-owned pharma-
ceutical company set up in 1968 to supply local and
regional markets) has considerable manufacturing capa-
city in solid and liquid dose forms and is GMP and ISO
9001-2000 certified. At one point it was strongly inter-
ested in plant medicine and produced an anti-malarial
teabag based on the herb moringa, which was to be
further developed through R&D. However, financial and
management constraints meant that this idea was aban-
doned, and the current CEO questioned whether it was
‘worth the risk’ to move into innovative products.
A more typical and very interesting approach to
‘scientific upgrading’ can be seen in the example of the
Plant Medicine Company Ltd. Incorporated in 2000, it
was founded and funded by a professor of organic
chemistry interested in making standardized traditional
medicine products of higher quality than are widely
available, though without efficacy trials. For the Plant
Medicine Company, the aim is to produce products
such as those for pain relief, diabetes and immune
boosting – mostly for local and regional markets, but
also international ones. Unlike pharmaceutical-based
companies, this firm has a direct link into the farming
of plant products. Indeed, the main barrier identified by
the CEO to sustainable commercialization was acquiring
plant materials. Taking the example of moringa, he sta-
ted that ‘a lot of people are planting it, but they don’t
know how to harvest it well. You know there’s a way of
harvesting it, a way of drying it, a way of storing it, and
so on and so forth. So again that is our biggest problem
for me in herbal medicine in Ghana’. Strong links into
the market were obvious with the company and the
CEO asserted that his familiarity with the local commu-
nity would naturally help to bring him sales.
A recent pertinent development in terms of plant
medicine product development is that an American-
Ghanaian firm, Phytica, has secured $1m funding from
the NDC government to conduct clinical trials for its
first product: an anti-malarial derived from the roots of
Cryptolepis sanguinolenta, a climbing shrub indigenous
to West Africa [45]. It is intended that trials will take
place through a public-private partnership with the
Noguchi Institute. According to the firm, complete stu-
dies of toxicity, bioavailability and pharmacokinetics of
the new formulation will be followed by a formal clinical
trial with hundreds of malaria patients. Though at an
early stage, this would mark a new approach to scientifi-
cally-upgrading plant medicine innovation, especially as
it is funded by local government rather than foreign
sources.
Across the different activities, we found very few firm-
firm linkages in the health sector in Ghana. A common
reason cited for this was lack of trust between groups,
leading to an unwillingness to collaborate or share infor-
mation. One CEO summed up this situation as ‘there’s
still proprietorship, father and mother kind of business’.
Firms were much more likely to have links with over-
seas firms, both in the North and the South, from which
inputs, knowledge and, in some cases, financing is
obtained. Nor could we find links between firms and the
local research community, except that firms hire gradu-
ates and give them on-the-job skills training.
The environment for these science-based firms work-
ing in the health field in Ghana is difficult. Regarding
financing, bank rates are considered far too high for
securing loans at around 20-25% - one interviewee stated
that ‘Ghana banks are not a place to look for money.
They don’t understand. To them, it’s just a commercial
venture, they don’t understand long-term profits’.
Another described the lending rate as ‘highway robbery’.
The firms we spoke to were largely self-funded through
personal investments, or from other revenue sources
such as services. If there was external funding, it was not
from within Ghana. For example, it was the LaGray man-
agement’s status as dual nationals with the US that
enabled them to access their initial investment from the
Overseas Private Investment Corporation (OPIC).
While the Ghana Stock Exchange was considered
reputable, it is not yet interested in technological ven-
tures in the health field; rather, it focuses on lower-risk
activities such as mining and real estate. Two local phar-
maceutical companies have floated on the GSE (Ayrton
and Starwin) but ‘the extent of capital attracted…is not
substantial’ [30] as the sector is seen to be undermined
by a reliance on international exports.
Venture capital is limited, and not attuned to the
needs of a small business in a developing country.
Rather, local venture capitalists reportedly adopt a ‘US
model’, and expect fully formed companies before
investing. The Government of Ghana Venture Capital
Trust Fund (VCTF) has been set up to provide invest-
ment capital to SMEs, with pharmaceuticals as one of
the priority sectors. However, to date the VCTF has not
invested in the health sector. While for some firms lack
of financing is a major barrier, others would rather grow
slowly without the threat of interference. One intervie-
wee, averse to venture capital, said ‘these people come
in and try to dominate you. I don’t like that. I’d rather
go at my pace and increase slowly, rather than saddling
myself with debt, and [having] people to come and tell
me what to do.’
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The competitive advantage for most firms, when com-
pared with those exporting products from India and
China, was their location and knowledge of the local
market. Firms had products registered all over West
Africa, and a common theme expressed by interviewees
was the competitive local market and the need for effec-
tive branding and marketing through television and
radio. There was also intense interest in any mechan-
isms that allowed for easier penetration of regional mar-
kets, such as regulatory harmonization. Access to
Francophone markets, is also a growing area where
Ghanaian manufacturers might be well-positioned. One
interviewee said that ‘the Indians have not yet under-
stood the Francophone market, which is good for me’.
However, the practical logistics of accessing markets
remain a major difficulty – the complexity of drug dis-
tribution meant that firms had to rely on building their
own networks, which is an expensive and time-consum-
ing endeavor. An NGO representative working on drug
distribution reiterated this difficulty: ‘each and every one
is developing his own distribution system, making it
very expensive for products to get to the people who
need them…my wish is that the market be consolidated
and move away from the highly fragmented nature that
it is now’.
One method to overcome this is to gain WHO pre-
qualification and be eligible to sell products to interna-
tional donors; a number of firms, already GMP
qualified, were attempting to do this. However, it is an
expensive (~$500,000) and cumbersome process. The
need to prove bioequivalence (the measure of the
equivalence of difference formulations of a drug in
terms of bioavailability in the body) was another
requirement causing difficulty for firms due to lack of
any facility for this on the continent outside South
Africa. A final point is that in general firms were not
seeking patents; other forms of secrecy are more preva-
lent, such as trade secrets. Even if a patent was obtained,
it would not necessarily be useful - costs would prohibit
protecting any infringement, for example.
Despite the fact that Ghana has tried hard to make
business attractive, few firms cited any support from
government, except for a policy of a 15% preferential
price adjustment to local firms and possible assistance
with gaining ISO qualification. As the role of SMEs in
the economy has risen in importance, so has the range
of programs to support them financially and through
training – e.g. Empretec, a non-governmental organiza-
tion for support of entrepreneurs; the National Board of
Small Scale Industries; and GRATIS, the public agency
responsible for tech development and transfer. However,
none of these were mentioned by our interviewees in
the health sector; this may be because such initiatives
tend to focus on ‘lower-tech’ health interventions, and
the area of science-based business is poorly understood.
Firms identified a range of areas where potential gov-
ernment support could be improved, including VAT
exemptions on a wider range of imported materials
necessary for pharmaceutical manufacturing, and incen-
tives to train staff and build capacity. One interviewee
simply wished for less bureaucracy, saying ‘there are
very cumbersome laws in Ghana, very basic things
which have nothing to do with pharma production….
they have to do with business.’ One example given was
the Ghana Investment Promotion Centre (GIPC) law
which was supposed to make the GIPC a ‘one-stop-
shop’ for businesses, but this efficiency has been under-
mined because an earlier investment law had not been
repealed. This highlights the difference between policy
and practice often evident in Ghana: ‘if the GIPC law
actually worked the way it’s supposed to work, it would
be wonderful’.
In the face of these challenges, the entrepreneurial
drive of the founders and their willingness to take risks
with their own assets is clear. One Ghanaian CEO com-
mented ‘people find me unusual, but I’ve always been
entrepreneurial, from childhood’. Almost all the foun-
ders were African but had been educated or worked in
the US or Europe, for varying lengths of time, attesting
to some element of brain circulation rather than simple
brain drain. These interviewees were driven towards
entrepreneurship by a combination of factors: the mar-
ket opportunity, a sense of challenge, and the strong
desire to ‘give back’ to Africa’. One CEO said that ‘as a
major shareholder, of course I want to maximize my
investment, but at the same time I also want to open
doors’.
NGOs and donors
As one of the favored African countries for donor aid, the
health sector in Ghana, including health research spon-
sored by the Ministry of Health, is heavily supported by
outside funding. Of the 19 donors active in Ghana’s
health sector between 2003 and 2005, the largest were
the World Bank ($136.9 million), the Netherlands
($103.9 million), the United Kingdom ($71.4 million), the
United States ($59.9 million) and Denmark ($37.8 mil-
lion) [46]. Other philanthropic agencies are also directly
involved in supporting the Ministry of Health’s research
institutes. The Navrongo Health Research Centre, for
example, is supported by Rockefeller Foundation, United
States Agency for International Development (USAID)
and National Institutes of Health (NIH), World Health
Organization, Meningitis Research Foundation, the Cana-
dian International Development Research Centre, and the
Bill & Melinda Gates Foundation.
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In the universities and research institutions, we found
that almost all of the biomedical research conducted in
Ghana, including biotechnology, was funded by national
development agencies and multilateral donors. Outside
support for such research has a number of positive
impacts in terms of knowledge generation, transfer of
expertise, local training and capacity building. However,
it can also be problematic. For example, donor priorities
don’t necessarily align with those of the research com-
munity, and funding streams can be erratic and discon-
tinuous; examples were found of projects in tuberculosis
and in vector control which were abandoned after fun-
der priorities changed. Some lack of clarity was shown
by interviewees around ownership of donor-funded
research results, and, in the area of plant medicine,
unease was expressed by a few interviewees who main-
tained that partners were further researching Ghanian
plants once they had taken them out of the country. It
is worth noting that a number of interviewees felt
strongly that aid has made people dependent on outside
solutions at the expense of local expertise.
Another interesting point with respect to health inno-
vation is that donor support tends to end at the research
level, and has not generally extended to assessing the
commercial potential of research or aiding in technology
transfer. Furthermore, while research institutions have
benefited from financing, firms find it very difficult to
access funds. This may be partly due to donor funding
being frequently tied to ‘pro-poor’ efforts which will
have direct effects on communities, rather than science-
based initiatives which may make a longer-term contri-
bution to economic development.
In terms of NGOs operating in the health product
innovation field – as opposed to health services – we
found very few. Technoserve, an NGO which supports
entrepreneurial activities mainly in the agriculture sector
in Ghana, had given a grant to one of the firms we
interviewed to allow it to assess the value of laboratory
services it was considering operating. Though largely
outside the scope of this study, a number of NGOs are
indirectly contributing to the health innovation system
through providing vital access to rural markets, capa-
city-building and skills development. Two examples of
note were MircoBusiness for Health, an NGO develop-
ing an innovative service model based around training
women in rural villages to provide affordable preventa-
tive health products in rural communities, and
INDEPTH, a not-for-profit which consists of 35 health
and demographic surveillance system sites in 18 coun-
tries in Africa, Asia and Oceania. INDEPTH is known
for its Young Scientist Capacity Building Program,
which in collaboration with Witwatersrand University of
South Africa offers a Masters degree in Field Epidemiol-
ogy to young scientists of the network, and is being
supported by The Bill & Melinda Gates Foundation to
develop capacity the conduct of GCP-compliant malaria
drug and vaccine trials. It has with this grant built or
strengthened 11 clinical trial sites to be involved in
phase III of RTS,S malaria vaccine trials in Africa [47].
Finally, the donor community is a very important mar-
ket for health products, and their priorities, policies and
procurement choices therefore affect the focus of local
innovators. Drugs for diseases classed as ‘priority ende-
mic diseases’ are almost entirely supplied by the donor
sector, particularly the Global Fund to Fight Aids,
Tuberculosis and Malaria [30], and largely sourced from
Indian and Chinese firms.
Conclusions
Strengths and good practices
Ghana is active in several areas which could underpin
science-based health innovation in the future. These
include several health and biosciences research and
training institutions with strong outside research lin-
kages and donor support; a relatively strong regulatory
system which is building capacity in other West African
countries; the beginnings of new funding forms such as
venture capital; and the return of a number of profes-
sionals from the diaspora, particularly in the private sec-
tor, bringing expertise and contacts. The attempt by the
Ministry of Health’s interest to spur a ‘health industry’
also signals an openness to creative policy thinking
which sees health not only as a social expense but also a
productive sphere. Importantly, a variety of health pro-
ducts and services are already being developed in
Ghana, which are innovative in the sense of being new
to the country and, in some cases, the continent. They
include essential medicines, raw pharmaceutical materi-
als and new formulations for pediatric use.
Ghana’s activities in commercializing traditional medi-
cine are perhaps especially worthy of note, as they
encompass a wide variety of initiatives at different stages
of development. Almost every interviewee in this study
highlighted the perceived potential in this area, based on
factors such as considerable local knowledge, increased
government interest in the area, and the large market
potential both at home and abroad. Ghana is ahead of
many other African countries in developing policies to
improve standards in traditional medicine practice and
products.
There is, however, a distinction between commerciali-
zation for local use, as is already occurring through
institutions such as the Centre for Scientific Research
into Plant Medicine, and producing products according
to international biomedical standards, which has been a
more elusive goal.Our study has focused on science-
based innovation, and shows that a number of institu-
tions exist that could contribute to scientific upgrading
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of traditional medicine Ghana’s capacity in this area, a
finding borne out elsewhere [48]. The recent funding of
a public-private partnership between a local firm and
the Noguchi Institute for Medical Research to conduct
clinical trials on a herbal anti-malarial is an interesting
development that would represent a very different
approach to traditional medicine product development
However, the complexity of issues around ownership
and benefit sharing still remain and will require consid-
erable attention, not least the passing of the draft Bill
for the protection of indigenous knowledge into law.
Recommendations
Innovative health activities in Ghana are generally being
driven by individual entrepreneurs relying on interna-
tional linkages for access to physical inputs, knowledge
and/or markets, who are not well-connected to other
local firms, research organizations or government bodies
(though there are exceptions such as the Food and
Drugs Board). They have received little local financial or
logistical support, and face major challenges to growth
and even sustainability. A key concern for them and for
other firms hoping to grow in this area is access to
knowledge (local or international) and to markets, be
they local, regional, or part of the global procurement
system; each of these pose their own difficulties.
Health and biomedical research institutions are contri-
buting to health innovation in a broad sense, primarily
through providing training. However Ghana’s continu-
ously low national support for health research has
resulted in deteriorating scientific infrastructure and low
morale of research staff working in the public sector,
particularly in research institutions. Demand for
research by industry has been poorly understood, pub-
lic-private links are weak and public sector commerciali-
zation policies, which have focused on the supply side,
have therefore been ineffective. The strong presence of
donors in funding health research, while helpful in keep-
ing science alive and supporting some excellent exam-
ples of knowledge transfer with public health
implications, is liable to be short-term and has not been
helpful in generating locally-owned knowledge or its
local commercialization.
In Ghana, the challenge at the policy level is not so
much the creation of policy documents, but rather in
their implementation and co-ordination with other pol-
icy aims and objectives. A series of S&T policies with
weak implementation has left researchers unmotivated,
and different elements of the innovation system working
independently without a coherent goal. Our research
showed different attitudes and commitment to S&T
across different government ministries, with no over-
arching leadership. A positive step is the recent reestab-
lishment of a Ministry for Environment, Science and
Technology, and the development of a national STI pol-
icy which explicitly considers innovation as well as S&T
[49]. The challenge now is to link this to concrete out-
comes and to economic and health goals.
While Ghana has a large number of institutions in the
public and private sector concerned with health research
and its commercialization, their ability to work together
to address clear health goals is low. Some strong lin-
kages are apparent – between health researchers and
the international research community, between local
firms and their (mostly international) suppliers, between
NGOs and the community. However, the systemic
aspect is absent and groups remain isolated from collec-
tively mobilizing research towards economically-produc-
tive and sustainable ends. Lack of trust between
stakeholders, unwillingness to share information, and
different working cultures were issues repeatedly
expressed by interviewees – issues which will only be
overcome through concerted efforts to forge partner-
ships around health goals, and create incentives for
firms to interact and share risk.
After our initial fieldwork in Ghana, we continued to
work with stakeholders who constitute the health and
biotechnology innovation sector. A working group on
health and biotechnology innovation was established,
with representation from government, the research com-
munity and the private sector. The group’s goals were to
consider how to build a sustainable hub in Ghana that
would help to link stakeholders, overcome barriers to
collaboration, and stimulate locally-relevant health inno-
vation. The group identified some key initial activities in
this regard, such as setting up a virtual network to bring
together stakeholders through the internet and regular
meetings; a technology roadshow that would showcase
Ghanaian technologies developed at research institutions
to a wider audience, including financiers; and creating a
database of technologies, infrastructure and equipment
within Ghana that could be easily accessed and help to
identify potential areas of cooperation. This novel
approach could in the long-term lead to more demand-
driven innovation in the health sector [50,51].
Based on our research, we suggest four recommenda-
tions to support health innovation in Ghana:
Recommendation 1: Support small firms to build cap-
abilities and access markets. A broad range of incentives
could be applicable here, such as support for firms to
undertake R&D; better financing instruments such as
lower banking rates and credit guarantee schemes; redu-
cing taxes on raw materials; improving conditions for
importing equipment; procurement of locally-developed
products; and improved market access through better
distribution systems and market knowledge. North-
South and South-South partnerships for knowledge and
technology transfer should also be encouraged. At a
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regional level, the possibility of regional regulatory har-
monization for health products should be pursued.
Finally, reviewing and removing old laws that are adding
unnecessary bureaucracy to small businesses, such as
the old Ghana Investment Promotion Law, would be
beneficial.
Recommendation 2: Increase national funding commit-
ment to S&T, and consider what types of donor health
research support could be most beneficial for innovation.
Ghana should at least reach the 1% of GDP target for
investment in S&T set by the African Union, and break
the cycle of dwindling support for science. Updating key
laboratory infrastructure where possible would be bene-
ficial. A more strategic approach to commercialization is
needed, perhaps around particular technology areas with
incentives for joint public-private research and develop-
ment. Dialogue with donors around the potential for
health research to better be linked to economic and
innovative activities and to generate locally-owned
knowledge would also be beneficial.
Recommendation 3: Set clear targets for implementa-
tion of STI policy for health and ensure coordination of
policies across government Ministries The most recent
STI policy – which includes innovation for the first time
– is a positive step. However, it remains broad and var-
ied in its goals and does not set measurable targets for
success around tangible health outcomes. If previous
problems with implementation are to be avoided, speci-
fic activities around health and health technologies need
to be identified and S&T, economic and health goals
and policies need to be aligned. Thought should also be
given to how to build a health industry which can
employ, challenge, and mobilize qualified personnel –
without local opportunities, brain drain will continue to
negatively affect the country. For this, complementary
policies will be needed around local manufacturing, pro-
curement, health, access, and business support.
Recommendation 4: Establish a focal point for health
innovation. Such a focal point would actively bring
together relevant stakeholders from the government,
research, private sector, donor and NGO communities.
This could build on the activities of the working group
on health innovation that was established during this
study. Their work would need to go beyond a commit-
tee or policy decision, as the same issues around knowl-
edge translation have been arising for many years in the
Ghanaian context. As has been shown by other
researchers of innovation in developing countries, ‘prac-
tical collaboration on concrete activities is essential’
[55], rather than overly ambitious projects or plans. In
the health context, this could perhaps occur through a
product development program around specific health
products, such as diagnostics, bednets, plant medicines,
or other nationally-determined health goals – perhaps
linked to import substitution for commonly-used health
products.
From our study, it can be concluded that Ghana’s
entrepreneurs are setting the stage for health innovation
activities, and that policies and support mechanisms
need to respond to these activities to ensure they grow.
The macroeconomic and political stability of the coun-
try, its strong health research networks and donor sup-
port mean that some fundamental factors are in
Ghana’s favor in capitalizing on health innovation to
address local needs, if they can be built upon. This is
demonstrated by the growing numbers of diaspora
returnees in the health sector who consider this the
right time for Ghana to build capacity in essential medi-
cine production. Crucially, mobilizing the large number
of disparate groups involved in addressing local health
is vital – not just as a social need, but also as an eco-
nomic opportunity which can generate jobs and build
self-sufficiency in health products. Recent activities,
such as support for a public-private partnership around
a plant anti-malarial, suggest that Ghana is ahead of the
curve and building on its long experience of develop-
ment with what have the potential to be groundbreak-
ing initiatives.
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